Hepion Pharmaceuticals, Inc.
HEPA · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.00 | -0.07 | -0.02 | 0.00 |
| FCF Yield | -630.49% | -319.61% | -166.39% | -39.29% |
| EV / EBITDA | -0.28 | 0.04 | 0.69 | 0.37 |
| Quality | ||||
| ROIC | -1,152.89% | -371.87% | -81.16% | -31.72% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 1.38 | 0.84 | 0.83 | 0.95 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | – | – |
| Free Cash Flow Growth | 55.46% | -16.94% | -11.55% | -92.92% |
| Safety | ||||
| Net Debt / EBITDA | -0.13 | 0.30 | 1.17 | 3.00 |
| Interest Coverage | -15.51 | -5,118.64 | -4,475.47 | -3,431.91 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -2,613.10 | -12,770.89 | -12,561.83 | -10,371.78 |